{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:35:10Z","timestamp":1783427710382,"version":"3.54.6"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-024-10446-2","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T10:03:16Z","timestamp":1728986596000},"page":"89-101","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["In-hospital initiation of sodium-glucose co-transporter-2 inhibitors in patients with acute heart failure"],"prefix":"10.1007","volume":"30","author":[{"given":"Muhammad Sameer","family":"Arshad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeena","family":"Jamil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriette G.C","family":"Van Spall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shahzeb","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,15]]},"reference":[{"issue":"15","key":"10446_CR1","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMOA2022190\/SUPPL_FILE\/NEJMOA2022190_DATA-SHARING.PDF","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, B\u00f6hm M, Choi DJ, Chopra V et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15):1413\u20131424. https:\/\/doi.org\/10.1056\/NEJMOA2022190\/SUPPL_FILE\/NEJMOA2022190_DATA-SHARING.PDF","journal-title":"N Engl J Med"},{"key":"10446_CR2","doi-asserted-by":"publisher","unstructured":"Fontes-Carvalho R, Santos-Ferreira D, Raz I, Marx N, Ruschitzka F, Cosentino F (2021) Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin. Eur J Prev Cardiol. https:\/\/doi.org\/10.1093\/EURJPC\/ZWAB034","DOI":"10.1093\/EURJPC\/ZWAB034"},{"issue":"19","key":"10446_CR3","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/J.JACC.2023.03.390\/SUPPL_FILE\/MMC1.DOCX","volume":"81","author":"J Butler","year":"2023","unstructured":"Butler J, Packer M, Siddiqi TJ, B\u00f6hm M, Brueckmann M, Januzzi JL, Verma S, Gergei I, Iwata T, Wanner C, Ferreira JP, Pocock SJ, Filippatos G, Anker SD, Zannad F (2023) Efficacy of empagliflozin in patients with heart failure across kidney risk categories. J Am Coll Cardiol 81(19):1902\u20131914. https:\/\/doi.org\/10.1016\/J.JACC.2023.03.390\/SUPPL_FILE\/MMC1.DOCX","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"10446_CR4","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMOA1911303","volume":"381","author":"JJV Mcmurray","year":"2019","unstructured":"Mcmurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, B\u011blohl\u00e1vek J, B\u00f6hm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Duk\u00e1t A, Ge J et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMOA1911303","journal-title":"N Engl J Med"},{"issue":"2","key":"10446_CR5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMOA2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS, Ponikowski P, Lopes RD, Verma S, Lapuerta P, Pitt B (2021) Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 384(2):117\u2013128. https:\/\/doi.org\/10.1056\/NEJMOA2030183","journal-title":"N Engl J Med"},{"issue":"37","key":"10446_CR6","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/EURHEARTJ\/EHAD195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M et al (2023) 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 44(37):3627\u20133639. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAD195","journal-title":"Eur Heart J"},{"issue":"5","key":"10446_CR7","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/J.CARDFAIL.2022.02.010","volume":"28","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS et al (2022) 2022 AHA\/ACC\/HFSA guideline for the management of heart failure. J Card Fail 28(5):e1\u2013e167. https:\/\/doi.org\/10.1016\/J.CARDFAIL.2022.02.010","journal-title":"J Card Fail"},{"issue":"4","key":"10446_CR8","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.016","volume":"105","author":"PE Stevens","year":"2024","unstructured":"Stevens PE, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, Herrington WG, Hill G, Inker LA, Kazanc\u0131o\u011flu R, Lamb E, Lin P, Madero M, McIntyre N, Morrow K, Roberts G, Sabanayagam D, Schaeffner E, Shlipak M et al (2024) KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105(4):S117\u2013S314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.016","journal-title":"Kidney Int"},{"issue":"5","key":"10446_CR9","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1002\/EHF2.14468","volume":"10","author":"T Averbuch","year":"2023","unstructured":"Averbuch T, Esfahani M, Khatib R, Kayima J, Miranda JJ, Wadhera RK, Zannad F, Pandey A, Van Spall HGC (2023) Pharmaco-disparities in heart failure: a survey of the affordability of guideline recommended therapy in 10 countries. ESC Hear Fail 10(5):3152\u20133163. https:\/\/doi.org\/10.1002\/EHF2.14468","journal-title":"ESC Hear Fail"},{"issue":"7","key":"10446_CR10","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1001\/JAMACARDIO.2023.1266","volume":"8","author":"JB Pierce","year":"2023","unstructured":"Pierce JB, Vaduganathan M, Fonarow GC, Ikeaba U, Chiswell K, Butler J, Devore AD, Heidenreich PA, Huang JC, Kittleson MM, Joynt Maddox KE, Linganathan KK, McDermott JJ, Owens AT, Peterson PN, Solomon SD, Vardeny O, Yancy CW, Greene SJ (2023) Contemporary use of sodium-glucose cotransporter-2 inhibitor therapy among patients hospitalized for heart failure with reduced ejection fraction in the US: the get with the guidelines-heart failure registry. JAMA Cardiol 8(7):652\u2013661. https:\/\/doi.org\/10.1001\/JAMACARDIO.2023.1266","journal-title":"JAMA Cardiol"},{"issue":"20","key":"10446_CR11","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/J.JACC.2021.08.064","volume":"78","author":"VN Rao","year":"2021","unstructured":"Rao VN, Murray E, Butler J, Cooper LB, Cox ZL, Fiuzat M, Green JB, Lindenfeld JA, McGuire DK, Nassif ME, O\u2019Brien C, Pagidipati N, Sharma K, Vaduganathan M, Vardeny O, Fonarow GC, Mentz RJ, Greene SJ (2021) In-hospital initiation of sodium glucose cotransporter-2 inhibitors for heart failure with reduced ejection fraction. J Am Coll Cardiol 78(20):2004. https:\/\/doi.org\/10.1016\/J.JACC.2021.08.064","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10446_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12933-023-02042-9\/FIGURES\/7","volume":"23","author":"J Chen","year":"2024","unstructured":"Chen J, Jiang C, Guo M, Zeng Y, Jiang Z, Zhang D, Tu M, Tan X, Yan P, Xu XM, Long Y, Xu Y (2024) Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis. Cardiovasc Diabetol 23(1):1\u201313. https:\/\/doi.org\/10.1186\/S12933-023-02042-9\/FIGURES\/7","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"10446_CR13","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","volume":"28","author":"AA Voors","year":"2022","unstructured":"Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, Ferreira JP, Nassif ME, Psotka MA, Tromp J, Borleffs CJW, Ma C, Comin-Colet J, Fu M, Janssens SP, Kiss RG, Mentz RJ, Sakata Y, Schirmer H et al (2022) The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med 28(3):568\u2013574. https:\/\/doi.org\/10.1038\/s41591-021-01659-1","journal-title":"Nat Med"},{"issue":"14","key":"10446_CR14","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/J.JACC.2024.02.009","volume":"83","author":"ZL Cox","year":"2024","unstructured":"Cox ZL, Collins SP, Hernandez GA, McRae AT, Davidson BT, Adams K, Aaron M, Cunningham L, Jenkins CA, Lindsell CJ, Harrell FE, Kampe C, Miller KF, Stubblefield WB, Lindenfeld JA (2024) Efficacy and safety of dapagliflozin in patients with acute heart failure. J Am Coll Cardiol 83(14):1295\u20131306. https:\/\/doi.org\/10.1016\/J.JACC.2024.02.009","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10446_CR15","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/EJHF.1713","volume":"22","author":"K Damman","year":"2020","unstructured":"Damman K, Beusekamp JC, Boorsma EM, Swart HP, Smilde TDJ, Elvan A, van Eck JWM, Heerspink HJL, Voors AA (2020) Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail 22(4):713\u2013722. https:\/\/doi.org\/10.1002\/EJHF.1713","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10446_CR16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1161\/CIRCULATIONAHA.122.059038","volume":"146","author":"PC Schulze","year":"2022","unstructured":"Schulze PC, Bogoviku J, Westphal J, Aftanski P, Haertel F, Grund S, Von Haehling S, Schumacher U, M\u00f6bius-Winkler S, Busch M (2022) Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF). Circulation 146(4):289\u2013298. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.059038","journal-title":"Circulation"},{"issue":"16","key":"10446_CR17","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1056\/NEJMOA2314051\/SUPPL_FILE\/NEJMOA2314051_DATA-SHARING.PDF","volume":"390","author":"J Butler","year":"2024","unstructured":"Butler J, Jones WS, Udell JA, Anker SD, Petrie MC, Harrington J, Mattheus M, Zwiener I, Amir O, Bahit MC, Bauersachs J, Bayes-Genis A, Chen Y, Chopra VK, Figtree G, Ge J, Goodman SG, Gotcheva N, Goto S et al (2024) Empagliflozin after acute myocardial infarction. N Engl J Med 390(16):1455\u20131466. https:\/\/doi.org\/10.1056\/NEJMOA2314051\/SUPPL_FILE\/NEJMOA2314051_DATA-SHARING.PDF","journal-title":"N Engl J Med"},{"key":"10446_CR18","doi-asserted-by":"publisher","unstructured":"Tavares CAM, Azevedo LCP, Rea-Neto \u00c1, Campos NS, Amendola CP, Kozesinski-Nakatani AC, David-Jo\u00e3o PG, Lobo SM, Filiponi TC, Almeida GMB, Bergo RR, Guimar\u00e3es-J\u00fanior MRR, Figueiredo RC, Castro JR, Schuler CJ, Westphal GA, Carioca ACR, Monfradini F, Nieri J et al (2024) Dapagliflozin for critically ill patients with acute organ dysfunction: the DEFENDER randomized clinical trial. JAMA. https:\/\/doi.org\/10.1001\/JAMA.2024.10510","DOI":"10.1001\/JAMA.2024.10510"},{"issue":"9","key":"10446_CR19","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/S2213-8587(21)00180-7","volume":"9","author":"MN Kosiborod","year":"2021","unstructured":"Kosiborod MN, Esterline R, Furtado RHM, Oscarsson J, Gasparyan SB, Koch GG, Martinez F, Mukhtar O, Verma S, Chopra V, Buenconsejo J, Langkilde AM, Ambery P, Tang F, Gosch K, Windsor SL, Akin EE, Soares RVP, Moia DDF et al (2021) Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 9(9):586\u2013594. https:\/\/doi.org\/10.1016\/S2213-8587(21)00180-7","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10446_CR20","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/S2213-8587(23)00253-X","volume":"11","author":"PW Horby","year":"2023","unstructured":"Horby PW, Martin P, Landray J (2023) Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Artic Lancet Diabetes Endocrinol. 11:905\u2013919. https:\/\/doi.org\/10.1016\/S2213-8587(23)00253-X","journal-title":"Artic Lancet Diabetes Endocrinol."},{"key":"10446_CR21","doi-asserted-by":"publisher","unstructured":"James S, Erlinge D, Storey RF, McGuire DK, de Belder M, Eriksson N, Andersen K, Austin D, Arefalk G, Carrick D, Hofmann R, Hoole SP, Jones DA, Lee K, Tygesen H, Johansson PA, Langkilde AM, Ridderstr\u00e5le W, Parvaresh Rizi E et al (2024) Dapagliflozin in myocardial infarction without diabetes or heart failure. NEJM Evid 3(2). https:\/\/doi.org\/10.1056\/evidoa2300286","DOI":"10.1056\/evidoa2300286"},{"key":"10446_CR22","unstructured":"ESC 365 - Management of acute and residual congestion in patients with acute heart failure by adding dapaglifozin to intravenous loop diuretic therapy-ENDORSE-HF. Accessed June 18, 2024. https:\/\/esc365.escardio.org\/presentation\/280201?query=endorse-hf"},{"key":"10446_CR23","doi-asserted-by":"publisher","unstructured":"Dixit NM, Shah S, Ziaeian B, Fonarow GC, Hsu JJ (2021) Optimizing guideline-directed medical therapies for heart failure with reduced ejection fraction during hospitalization. US Cardiol Rev 15. https:\/\/doi.org\/10.15420\/USC.2020.29","DOI":"10.15420\/USC.2020.29"},{"issue":"9","key":"10446_CR24","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1002\/EJHF.2971","volume":"25","author":"D Stolfo","year":"2023","unstructured":"Stolfo D, Lund LH, Benson L, Lindberg F, Ferrannini G, Dahlstr\u00f6m U, Sinagra G, Rosano GMC, Savarese G (2023) Real-world use of sodium\u2013glucose cotransporter 2 inhibitors in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry. Eur J Heart Fail 25(9):1648\u20131658. https:\/\/doi.org\/10.1002\/EJHF.2971","journal-title":"Eur J Heart Fail"},{"issue":"8 Pt 1","key":"10446_CR25","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/J.JCHF.2023.03.024","volume":"11","author":"A Hussain","year":"2023","unstructured":"Hussain A, Ramsey D, Lee M, Mahtta D, Khan MS, Nambi V, Ballantyne CM, Petersen LA, Walker AD, Kayani WT, Butler J, Slipczuk L, Rogers JG, Bozkurt B, Navaneethan SD, Virani SS (2023) Utilization rates of SGLT2 inhibitors among patients with type 2 diabetes, heart failure, and atherosclerotic cardiovascular disease: insights from the department of veterans affairs. JACC Heart Fail 11(8 Pt 1):933\u2013942. https:\/\/doi.org\/10.1016\/J.JCHF.2023.03.024","journal-title":"JACC Heart Fail"},{"issue":"1","key":"10446_CR26","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3390\/DIABETOLOGY4010010","volume":"4","author":"J Selwyn","year":"2023","unstructured":"Selwyn J, Pichardo-Lowden AR (2023) Managing hospitalized patients taking SGLT2 inhibitors: reducing the risk of euglycemic diabetic ketoacidosis. Diabetol 4(1):86\u201392. https:\/\/doi.org\/10.3390\/DIABETOLOGY4010010","journal-title":"Diabetol"},{"key":"10446_CR27","doi-asserted-by":"crossref","unstructured":"Oskouie S, Pandey A, Sauer AJ, Greene SJ, Mullens W, Khan MS, Quinn KL, Ho JE, Albert NM, Van Spall HGC (2024) From hospital to home: evidence-based care for worsening heart failure. JACC Adv","DOI":"10.1016\/j.jacadv.2024.101131"},{"issue":"5","key":"10446_CR28","doi-asserted-by":"publisher","first-page":"514","DOI":"10.4239\/WJD.V12.I5.514","volume":"12","author":"P Nasa","year":"2021","unstructured":"Nasa P, Chaudhary S, Shrivastava PK, Singh A (2021) Euglycemic diabetic ketoacidosis: a missed diagnosis. World J Diabetes 12(5):514. https:\/\/doi.org\/10.4239\/WJD.V12.I5.514","journal-title":"World J Diabetes"},{"issue":"5","key":"10446_CR29","doi-asserted-by":"publisher","first-page":"7691","DOI":"10.18632\/AGING.202593","volume":"13","author":"M Zhu","year":"2021","unstructured":"Zhu M, Liu X, Liu W, Lu Y, Cheng J, Chen Y (2021) \u03b2 cell aging and age-related diabetes. Aging (Albany NY) 13(5):7691. https:\/\/doi.org\/10.18632\/AGING.202593","journal-title":"Aging (Albany NY)"},{"issue":"Suppl 1","key":"10446_CR30","doi-asserted-by":"publisher","first-page":"S154","DOI":"10.2337\/DC18-SDIS01","volume":"41","author":"Professional Practice Committee","year":"2018","unstructured":"Professional Practice Committee (2018) American College of Cardiology-Designated Representatives, and American Diabetes Association Staff Disclosures. Diabetes Care 41(Suppl 1):S154\u2013S155. https:\/\/doi.org\/10.2337\/DC18-SDIS01","journal-title":"Diabetes Care"},{"issue":"8","key":"10446_CR31","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1210\/CLINEM\/DGAC278","volume":"107","author":"MT Korytkowski","year":"2022","unstructured":"Korytkowski MT, Muniyappa R, Antinori-Lent K, Donihi AC, Drincic AT, Hirsch IB, Luger A, McDonnell ME, Murad MH, Nielsen C, Pegg C, Rushakoff RJ, Santesso N, Umpierrez GE (2022) Management of hyperglycemia in hospitalized adult patients in non-critical care settings: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 107(8):2101\u20132128. https:\/\/doi.org\/10.1210\/CLINEM\/DGAC278","journal-title":"J Clin Endocrinol Metab"},{"key":"10446_CR32","doi-asserted-by":"publisher","unstructured":"Mazidi M, Rezaie P, Gao HK, Kengne AP (2017) Effect of Sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart Assoc 6(6). https:\/\/doi.org\/10.1161\/JAHA.116.004007","DOI":"10.1161\/JAHA.116.004007"},{"issue":"6","key":"10446_CR33","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3390\/MEDICINA59061047","volume":"59","author":"CD Moschopoulos","year":"2023","unstructured":"Moschopoulos CD, Dimopoulou D, Dimopoulou A, Dimopoulou K, Protopapas K, Zavras N, Tsiodras S, Kotanidou A, Fragkou PC (2023) New Insights into the fluid management in patients with septic shock. Med 59(6):1047. https:\/\/doi.org\/10.3390\/MEDICINA59061047","journal-title":"Med"},{"issue":"5","key":"10446_CR34","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/JHM.12798","volume":"17","author":"SS Sata","year":"2022","unstructured":"Sata SS, Spratt SE, Edmonston DL, Pagidipati N (2022) Clinical progress note: indications for and management of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in hospitalized patients. J Hosp Med 17(5):360\u2013363. https:\/\/doi.org\/10.1002\/JHM.12798","journal-title":"J Hosp Med"},{"issue":"6","key":"10446_CR35","doi-asserted-by":"publisher","first-page":"837","DOI":"10.4103\/IJEM.IJEM_159_17","volume":"22","author":"AG Unnikrishnan","year":"2018","unstructured":"Unnikrishnan AG, Kalra S, Purandare V, Vasnawala H (2018) Genital infections with sodium glucose cotransporter-2 inhibitors: occurrence and management in patients with type 2 diabetes mellitus. Indian J Endocrinol Metab 22(6):837. https:\/\/doi.org\/10.4103\/IJEM.IJEM_159_17","journal-title":"Indian J Endocrinol Metab"},{"issue":"1","key":"10446_CR36","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/BCP.13782","volume":"85","author":"S Adimadhyam","year":"2019","unstructured":"Adimadhyam S, Schumock GT, Calip GS, Smith Marsh DE, Layden BT, Lee TA (2019) Increased risk of mycotic infections associated with sodium\u2013glucose co-transporter 2 inhibitors: a prescription sequence symmetry analysis. Br J Clin Pharmacol 85(1):160\u2013168. https:\/\/doi.org\/10.1111\/BCP.13782","journal-title":"Br J Clin Pharmacol"},{"issue":"15","key":"10446_CR37","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/J.JACC.2023.12.024\/SUPPL_FILE\/MMC1.PDF","volume":"83","author":"TM Maddox","year":"2024","unstructured":"Maddox TM, Januzzi JL, Allen LA, Breathett K, Brouse S, Butler J, Davis LL, Fonarow GC, Ibrahim NE, Lindenfeld JA, Masoudi FA, Motiwala SR, Oliveros E, Walsh MN, Wasserman A, Yancy CW, Youmans QR (2024) 2024 ACC expert consensus decision pathway for treatment of heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 83(15):1444\u20131488. https:\/\/doi.org\/10.1016\/J.JACC.2023.12.024\/SUPPL_FILE\/MMC1.PDF","journal-title":"J Am Coll Cardiol"},{"issue":"Supplement_1","key":"10446_CR38","doi-asserted-by":"publisher","first-page":"S179","DOI":"10.2337\/DC24-S010","volume":"47","author":"ADAPP Committee","year":"2024","unstructured":"Committee ADAPP, ElSayed NA, Aleppo G, Bannuru RR, Bruemmer D, Collins BS, Das SR, Ekhlaspour L, Hilliard ME, Johnson EL, Khunti K, Kosiborod MN, Lingvay I, Matfin G, McCoy RG, Lou PM, Pilla SJ, Polsky S, Prahalad P et al (2024) 10. Cardiovascular disease and risk management: standards of care in diabetes\u20142024. Diabetes Care 47(Supplement_1):S179\u2013S218. https:\/\/doi.org\/10.2337\/DC24-S010","journal-title":"Diabetes Care"},{"issue":"4","key":"10446_CR39","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.cjca.2021.01.017","volume":"37","author":"M McDonald","year":"2021","unstructured":"McDonald M, Virani S, Chan M, Ducharme A, Ezekowitz JA, Giannetti N, Heckman GA, Howlett JG, Koshman SL, Lepage S, Mielniczuk L, Moe GW, O\u2019Meara E, Swiggum E, Toma M, Zieroth S, Anderson K, Bray SA, Clarke B et al (2021) CCS\/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction. Can J Cardiol 37(4):531\u2013546. https:\/\/doi.org\/10.1016\/j.cjca.2021.01.017","journal-title":"Can J Cardiol"},{"issue":"5","key":"10446_CR40","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/J.EPRAC.2023.02.001","volume":"29","author":"SL Samson","year":"2023","unstructured":"Samson SL, Vellanki P, Blonde L, Christofides EA, Galindo RJ, Hirsch IB, Isaacs SD, Izuora KE, Low Wang CC, Twining CL, Umpierrez GE, Valencia WM (2023) American Association of Clinical Endocrinology Consensus Statement: comprehensive type 2 diabetes management algorithm \u2013 2023 Update. Endocr Pract 29(5):305\u2013340. https:\/\/doi.org\/10.1016\/J.EPRAC.2023.02.001","journal-title":"Endocr Pract"},{"issue":"1","key":"10446_CR41","first-page":"14","volume":"65","author":"NM Ivers","year":"2019","unstructured":"Ivers NM, Jiang M, Alloo J, Singer A, Ngui D, Casey CG, Yu CH (2019) Diabetes Canada 2018 clinical practice guidelines: key messages for family physicians caring for patients living with type 2 diabetes. Can Fam Physician 65(1):14","journal-title":"Can Fam Physician"},{"key":"10446_CR42","doi-asserted-by":"publisher","unstructured":"(2022) RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2022. Int J Diabetes Dev Ctries 42(Suppl 1):1. https:\/\/doi.org\/10.1007\/S13410-022-01129-5","DOI":"10.1007\/S13410-022-01129-5"},{"key":"10446_CR43","doi-asserted-by":"publisher","unstructured":"Gerontology NC of, Geriatrics CS of, Association DPC of CAW, Gerontology NC of, Geriatrics CS of, association DPC of CAW (2024) Guideline for the management of diabetes mellitus in the elderly in China (2024 edition). Med J Peking Union Med Coll Hosp. https:\/\/doi.org\/10.12290\/XHYXZZ.2024-0347","DOI":"10.12290\/XHYXZZ.2024-0347"},{"issue":"1","key":"10446_CR44","doi-asserted-by":"publisher","first-page":"pocj.5000200","DOI":"10.5301\/POCJ.5000200","volume":"2","author":"G Regolisti","year":"2016","unstructured":"Regolisti G, Antoniotti R, Pastorini G, Fani F, Fiaccadori E (2016) Management of congestion and diuretic resistance in heart failure. Nephrol Point Care 2(1):pocj.5000200. https:\/\/doi.org\/10.5301\/POCJ.5000200","journal-title":"Nephrol Point Care"},{"issue":"6","key":"10446_CR45","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1002\/EHF2.14157","volume":"9","author":"S Odajima","year":"2022","unstructured":"Odajima S, Fujimoto W, Kuroda K, Yamashita S, Imanishi J, Iwasaki M, Todoroki T, Okuda M, Hayashi T, Konishi A, Shinohara M, Toh R, Hirata K-i, Tanaka H (2022) Association of congestion with worsening renal function in acute decompensated heart failure according to age. ESC Hear Fail 9(6):4250. https:\/\/doi.org\/10.1002\/EHF2.14157","journal-title":"ESC Hear Fail"},{"issue":"4","key":"10446_CR46","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/J.JACC.2019.11.031","volume":"75","author":"TA Zelniker","year":"2020","unstructured":"Zelniker TA, Braunwald E (2020) Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol 75(4):422\u2013434. https:\/\/doi.org\/10.1016\/J.JACC.2019.11.031","journal-title":"J Am Coll Cardiol"},{"key":"10446_CR47","doi-asserted-by":"publisher","unstructured":"Ferreira JP, Blatchford JP, Teerlink JR, Kosiborod MN, Angermann CE, Biegus J, Collins SP, Tromp J, Nassif ME, Psotka MA, Comin-Colet J, Mentz RJ, Brueckmann M, Nordaby M, Ponikowski P, Voors AA (2024) Time from admission to randomization and the effect of empagliflozin in acute heart failure: a post-hoc analysis from EMPULSE. Eur J Heart Fail. https:\/\/doi.org\/10.1002\/EJHF.3369","DOI":"10.1002\/EJHF.3369"},{"issue":"2","key":"10446_CR48","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/J.AHJ.2015.05.003","volume":"170","author":"JM Ter Maaten","year":"2015","unstructured":"Ter Maaten JM, Dunning AM, Valente MAE, Damman K, Ezekowitz JA, Califf RM, Starling RC, Van Der Meer P, O\u2019Connor CM, Schulte PJ, Testani JM, Hernandez AF, Tang WHW, Voors AA (2015) Diuretic response in acute heart failure\u2014an analysis from ASCEND-HF. Am Heart J 170(2):313\u2013321.e4. https:\/\/doi.org\/10.1016\/J.AHJ.2015.05.003","journal-title":"Am Heart J"},{"issue":"10","key":"10446_CR49","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/S00392-013-0588-8","volume":"102","author":"JP Ferreira","year":"2013","unstructured":"Ferreira JP, Santos M, Almeida S, Marques I, Bettencourt P, Carvalho H (2013) Tailoring diuretic therapy in acute heart failure: insight into early diuretic response predictors. Clin Res Cardiol 102(10):745\u2013753. https:\/\/doi.org\/10.1007\/S00392-013-0588-8","journal-title":"Clin Res Cardiol"},{"issue":"10","key":"10446_CR50","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1002\/EJHF.2982","volume":"25","author":"JP Ferreira","year":"2023","unstructured":"Ferreira JP, Blatchford JP, Teerlink JR, Kosiborod MN, Angermann CE, Biegus J, Collins SP, Tromp J, Nassif ME, Psotka MA, Comin-Colet J, Mentz RJ, Brueckmann M, Nordaby M, Ponikowski P, Voors AA (2023) Mineralocorticoid receptor antagonist use and the effects of empagliflozin on clinical outcomes in patients admitted for acute heart failure: findings from EMPULSE. Eur J Heart Fail 25(10):1797\u20131805. https:\/\/doi.org\/10.1002\/EJHF.2982","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10446_CR51","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1002\/EJHF.2681","volume":"24","author":"AA Voors","year":"2022","unstructured":"Voors AA, Damman K, Teerlink JR, Angermann CE, Collins SP, Kosiborod M, Biegus J, Ferreira JP, Nassif ME, Psotka MA, Tromp J, Brueckmann M, Blatchford JP, Salsali A, Ponikowski P (2022) Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial. Eur J Heart Fail 24(10):1844. https:\/\/doi.org\/10.1002\/EJHF.2681","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"10446_CR52","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/S40265-022-01730-2","volume":"82","author":"T Koufakis","year":"2022","unstructured":"Koufakis T, Mustafa OG, Ajjan RA, Garcia-Moll X, Zebekakis P, Dimitriadis G, Kotsa K (2022) From skepticism to hope: the evolving concept of the initiation and use of sodium-glucose cotransporter 2 inhibitors in hospitalized patients. Drugs 82(9):949. https:\/\/doi.org\/10.1007\/S40265-022-01730-2","journal-title":"Drugs"},{"issue":"3","key":"10446_CR53","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/J.MCNA.2016.12.011","volume":"101","author":"M Fayfman","year":"2017","unstructured":"Fayfman M, Pasquel FJ, Umpierrez GE (2017) Management of hyperglycemic crises: diabetic ketoacidosis and hyperglycemic hyperosmolar state. Med Clin North Am 101(3):587. https:\/\/doi.org\/10.1016\/J.MCNA.2016.12.011","journal-title":"Med Clin North Am"},{"issue":"1","key":"10446_CR54","doi-asserted-by":"publisher","first-page":"e001238","DOI":"10.1136\/BMJDRC-2020-001238","volume":"8","author":"AP McGovern","year":"2020","unstructured":"McGovern AP, Hogg M, Shields BM, Sattar NA, Holman RR, Pearson ER, Hattersley AT, Jones AG, Dennis JM (2020) Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open Diabetes Res Care. 8(1):e001238. https:\/\/doi.org\/10.1136\/BMJDRC-2020-001238","journal-title":"BMJ Open Diabetes Res Care."},{"issue":"Supplement_C","key":"10446_CR55","doi-asserted-by":"publisher","first-page":"C309","DOI":"10.1093\/EURHEARTJSUPP\/SUAD055","volume":"25","author":"L Monzo","year":"2023","unstructured":"Monzo L, Ferrari I, Cicogna F, Tota C, Cice G, Girerd N, Cal\u00f2 L (2023) Sodium-glucose co-transporter 2 inhibitors in heart failure: an updated evidence-based practical guidance for clinicians. Eur Hear J Suppl 25(Supplement_C):C309\u2013C315. https:\/\/doi.org\/10.1093\/EURHEARTJSUPP\/SUAD055","journal-title":"Eur Hear J Suppl"},{"issue":"2","key":"10446_CR56","doi-asserted-by":"publisher","first-page":"202","DOI":"10.33963\/KP.A2021.0172","volume":"80","author":"JA Borovac","year":"2022","unstructured":"Borovac JA, Kurir TT, Mustapic I, Kumric M, Bozic J, Glavas D, D\u2019Amario D (2022) SGLT2 inhibitors and the risk of urinary tract infections in patients with heart failure: a pooled analysis examining safety endpoints. Kardiol Pol 80(2):202\u2013204. https:\/\/doi.org\/10.33963\/KP.A2021.0172","journal-title":"Kardiol Pol"},{"key":"10446_CR57","doi-asserted-by":"publisher","first-page":"876","DOI":"10.3390\/BIOMEDICINES11030876","volume":"11","author":"M Nakagaito","year":"2023","unstructured":"Nakagaito M, Imamura T, Ushijima R, Nakamura M, Kinugawa K (2023) Predictors and outcomes of SGLT2 Inhibitor discontinuation in a real-world population after hospitalization for heart failure. Biomed 11:876. https:\/\/doi.org\/10.3390\/BIOMEDICINES11030876","journal-title":"Biomed"},{"issue":"16","key":"10446_CR58","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMOA2107038\/SUPPL_FILE\/NEJMOA2107038_DATA-SHARING.PDF","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Pi\u00f1a IL et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385(16):1451\u20131461. https:\/\/doi.org\/10.1056\/NEJMOA2107038\/SUPPL_FILE\/NEJMOA2107038_DATA-SHARING.PDF","journal-title":"N Engl J Med"},{"issue":"12","key":"10446_CR59","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMOA2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang CE, Borleffs CJW, Comin-Colet J, Dobreanu D, Drozdz J et al (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387(12):1089\u20131098. https:\/\/doi.org\/10.1056\/NEJMOA2206286","journal-title":"N Engl J Med"},{"key":"10446_CR60","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.3390\/JCM13113196","volume":"13","author":"M Nakagaito","year":"2024","unstructured":"Nakagaito M, Imamura T, Ushijima R, Nakamura M, Kinugawa K (2024) The impact of the withdrawal of SGLT2 inhibitors on clinical outcomes in patients with heart failure. J Clin Med 13:3196. https:\/\/doi.org\/10.3390\/JCM13113196","journal-title":"J Clin Med"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-024-10446-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-024-10446-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-024-10446-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T07:09:14Z","timestamp":1734160154000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-024-10446-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["10446"],"URL":"https:\/\/doi.org\/10.1007\/s10741-024-10446-2","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,15]]},"assertion":[{"value":"28 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Greene has received research support from the Duke University Department of Medicine Chair\u2019s Research Award, American Heart Association, Amgen, AstraZeneca, Boehinger Ingelheim, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, Pfizer, and Sanofi; has served on advisory boards or as consultant for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Corcept Therapeutics, Corteria Pharmaceuticals, CSL Vifor, Cytokinetics, Eli Lilly, Lexicon, Merck, Novo Nordisk, Otsuka, Roche Diagnostics, Sanofi, scPharmaceuticals, Tricog Health, and Urovant Pharmaceuticals; and has received speaker fees from AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Lexicon, and Roche Diagnostics; Dr. Van Spall is funded by the Canadian Institutes of Health Research and the Heart and Stroke Foundation of Canada, and is a consultant to Bayer and Medtronic; Dr. Fonarow has received research funding from the National Institutes of Health and has received consulting fees from Abbott, Amgen, AstraZeneca, Bayer, CHF Solutions, Edwards Lifesciences, Janssen, Medtronic, Merck, and Novartis;\u00a0Dr. Butler is consultant to Abbott, American Regent, Amgen, Applied Therapeutic, AskBio, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardiac Dimension, Cardiocell, Cardior, CSL Bearing, CVRx, Cytokinetics, Daxor, Edwards, Element Science, Faraday, Foundry, G3P, Innolife, Impulse Dynamics, Imbria, Inventiva, Ionis, Levator, Lexicon, Lilly, LivaNova, Janssen, Medtronics, Merck, Occlutech, Owkin, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, Pharmain, Prolaio, Pulnovo, Regeneron, Renibus, Roche, Salamandra, Salubris, Sanofi, SC Pharma, Secretome, Sequana, SQ Innovation, Tenex, Tricog, Ultromics, Vascular Dynamics, Vifor, and Zoll. Dr.Khan has received fees from Bayer; Dr. Arshad\u00a0and Dr. Jamil have no relevant competing interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}